The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health ...

NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer ...

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...